Oncolytic viruses: The tiny warriors fighting brain cancer
Brain cancer, notorious for its aggressiveness and limited treatment options, may finally have a powerful ally.A patient at ...
pharmaphorum3d
Big pharma could turn to viruses to boost cancer immunotherapies
Merck & Co’s $394 million acquisition of Viralytics has stoked interest in oncolytic viruses, a class of drugs that have been in the shadow of the checkpoint inhibitors and CAR-T therapies that ...
CURE17h
Progress Reported in Phase 1 Trial of CLD-101 for Recurrent Glioma
A progress report for a phase 1 trial of CLD-101 in recurrent glioma shows safety and feasibility at multiple intracerebral ...
China’s modified virus therapy shows promise in last-stage cancer trials
A new cancer therapy utilising a genetically modified herpes simplex virus type 1 (HSV-1) offers hope for late-stage patients ...
Tumour meltdown in China therapy tests offers hope to late-stage cancer patients
Experimental therapy uses a modified virus to boost immunity and make anti-tumour treatments more effective, according to ...
pharmaphorum2d
Oncolytics: the dawn of a new era in cancer treatment
Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major breakthrough in cancer treatment following the success of checkpoint inhibitors in immunotherapy.
CURE1d
Olvi-Vec Shows Responses and Tolerable Safety in Small Cell Lung Cancer
Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.
Biomednewsbreaks - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Encouraging Progress In Brain Cancer Trial With City Of Hope
Calidi Biotherapeutics (NYSE American: CLDI) announced promising early results from a phase 1 clinical trial evaluating its CLD-101 investigational ...